4 of P2A patients are treatment naive, those are ones who could be expected to have VA improve, but yes rest who have received existing SOC, its all about maintaining their prior gains.
I’m not saying AAVL’s phase-1 AMD data were bad, but rather that they weren’t great. I have doubts that AVA-101 will show much benefit when added to SoC in a large, double-masked randomized trial.
Market Data 
Markets 
AI
